Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter, the fund ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on HCA Healthcare (HCA – Research Report), ...

(2) Represents stock-based compensation expense and 401(k) match expense. The Company matches a portion of Exact Sciences employees’ contributions annually in the form of the Company’s common ...

BTIG analyst Mark Massaro reiterated a Hold rating on Alpha Teknova (TKNO – Research Report) today. The company’s shares closed ...

While scientists know there’s water on the Moon, its exact locations and forms remain largely unknown. A trailblazing NASA mission will get some answers. NASA's Lunar Trailblazer mission, designed to ...

It also incorporates enhanced sample stability components to provide patients more time to return their sample to Exact Sciences' lab and increase the valid result rate. Exact Sciences expects to ...

Precision Oncology revenues are likely to have been boosted by laboratory service revenues from global Oncotype DX and therapy selection tests. Exact Sciences has increased Oncotype DX adoption ...